A meta-analysis of 12 studies with a total of 13,254 participants and 5,007 cases of prostate cancer (PCa) showed that prostate cancer (PCa) risk decreased with increasing plasma/serum selenium up to 170 ng/mL.
Three high-quality studies of toenail selenium and cancer risk indicated a reduction in prostate cancer risk (estimated relative risk: 0.29) with a toenail selenium concentration between 0.85 and 0.94 µg/g, investigators reported in The American Journal of Clinical Nutrition (2012;96:111-122).
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.